NEW YORK (Reuters Health) – Women with early-stage estrogen receptor-positive breast cancer fare somewhat better with 2 years of tamoxifen followed by 3 years of anastrozole than with 5 years of tamoxifen, an Austrian group reports in the...
Famed Sex Expert, Dr. Ruth Westheimer, publishes a new book titled “Sexually Speaking: What Every Woman Needs to Know About Sexual Health.” In it, she covers a wide variety of topics, ranging from the best way to ensure you get proper...
NEW YORK (Reuters Health) – Results of a study suggest that gonadotropin-releasing hormone (GnRH) agonist therapy does not help preserve ovarian function in young women undergoing modern chemotherapy for early breast cancer.
GnRH agonist therapy...
In an article published in July 9, 2009 issue of The New England Journal of Medicine, Dr. Daniel Clarke-Pearson, chair of the department of obstetrics and gynecology at the University of North Carolina Chapel Hill School of Medicine, reviews the...
NEW YORK (Reuters Health) – All women found to have vulvar intraepithelial neoplasia (VIN) require some form of treatment and follow-up surveillance, according to recommendations from The American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice.
“Three modes of therapy...
NEW YORK (Reuters Health) – Elderly women who take more than 10 seconds to rise from a chair, walk 3 meters and return to sit down have a increased risk of fracture, independent of other factors such as bone mineral density (BMD), new research indicates.
The so-called ‘timed up and go’ (TUG)...
NEW YORK (Reuters Health) – Administering 17-alpha-hyroxyprogesterone caproate to women with multiple pregnancy does not reduce the preterm birth rate or consequent neonatal morbidity, a Dutch study has shown.
“In fact, there were slightly more preterm births in the 17-alpha-hydroxyprogesterone caproate...